Can maternal vaccination protect infants from RSV alongside nirsevimab?
Maternal RSV vaccination and nirsevimab are different tools that can be used together. Nirsevimab is a long-lasting antibody given directly to the baby that reduces hospitalizations by 70–90% 1. Maternal vaccination passes antibodies from the mother to the fetus during pregnancy, offering protection to the newborn before birth 9.
What the research says
Nirsevimab is designed to provide durable protection against RSV in infants, reducing hospitalizations significantly with no evidence of the virus escaping the antibody's reach 1. This drug targets a specific part of the virus that is hard for the virus to change, ensuring the protection lasts through the first RSV season 1.
Maternal vaccination is a separate strategy that protects the infant during their most vulnerable early months by transferring immunity from the mother 9. Research shows this approach has proven highly effective in other conditions like pertussis and influenza, making it a strong candidate for RSV prevention 9.
Breastfeeding also plays a key role alongside these medical interventions. It reduces the rate and severity of RSV outcomes, including hospitalization and mortality, acting as a synergistic non-pharmacological approach 10. Combining maternal vaccination, nirsevimab, and breastfeeding creates a layered defense for infants.
What to ask your doctor
- How does nirsevimab timing align with my pregnancy plan for maternal RSV vaccination?
- What are the current recommendations for using maternal vaccination alongside nirsevimab in my region?
- How does breastfeeding complement the protection provided by maternal vaccination and nirsevimab?
- Are there specific RSV strains that nirsevimab targets, and how might that affect my baby's protection?
This question is drawn from common patient questions about Infectious Disease and answered using cited medical research. We do not provide individualized advice.